Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
October 31, 2023
FDA-compliant manufacture of intravenous Ketamine is a required component of a New Drug Application Intravenous Ketamine has become widely used for treating depression and suicidality but has...
-
October 26, 2023
"Study May Proceed" letter received from FDA IND preclinical requirements are consistent with studies already in progress to support treatment of Bipolar Depression Potential to initiate...
-
October 12, 2023
Previously announced data sharing agreement for intravenous ketamine Newly available data highlight the need for a labeled form of IV ketamine that can qualify for insurance reimbursement Need for...
-
October 5, 2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chief Scientist of NRx...
-
October 2, 2023
Allows initiation of the NRX-101 commercial development to treat Chronic Pain Company plans to seek Fast Track and Breakthrough Therapy Designations from FDA while awaiting near-term results of...
-
September 20, 2023
Focus on implications of the recent Data Sharing Agreement relating to a landmark trial of Ketamine in the treatment of Suicidal Depression NMDA antagonist highly effective in Bipolar subgroup...
-
September 18, 2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard, J.D., Chief Executive Officer and Dr.
-
September 15, 2023
Ketamine, an NMDA blocker, was highly effective in Bipolar subgroup (p<0.001) NRx plans to present the data to FDA with a goal of identifying a path to an NDA RADNOR, Pa., Sept. 15, 2023...
-
September 14, 2023
Industry veteran Richard Narido joins the NRx Pharmaceuticals management team RADNOR, Pa., Sept. 14, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the...
-
September 7, 2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard, J.D., Chief Executive Officer and Dr.
-
September 6, 2023
NRX-101 demonstrated potent antibacterial effect against antibiotic-resistant pathogens in culture medium and in an artificial urine model D-cycloserine (DCS), a key component of NRX-101, was...
-
August 30, 2023
IND builds on previously-published, preliminary evidence of efficacy Filing is supported by robust manufacturing, pre-clinical and clinical data already reviewed by FDA for NRX-101 associated with...
-
August 29, 2023
NRx Pharmaceuticals received approximately $1.2 million in cash from existing investors Preferred shares to sold at $0.40; shares convert to one common share and one common warrant ($0.40/ strike)...
-
August 14, 2023
Two near-term data catalysts expected in 2023 Entered active collaboration with Alvogen Pharmaceuticals and Lotus Pharmaceuticals for global development and commercialization of NRX-101 in...
-
August 7, 2023
NRx has Licensed US Patent 8,653,120 for use of D-Cycloserine to treat Chronic Pain Dr. Vania Apkarian, a world leader in pain and D-Cycloserine (DCS) research, has joined the NRx Scientific...
-
August 7, 2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceutical company, today announced that it will release its second quarter 2023 financial...
-
June 20, 2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard, J.D., Chief Executive Officer and Dr.
-
June 9, 2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has closed its previously announced...
-
June 6, 2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has entered into definitive agreements for...
-
June 5, 2023
NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for...
-
June 2, 2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it will host a corporate and strategic update...
-
May 16, 2023
Enrollment continues in the Phase 2b/3 clinical trial evaluating NRX-101 in Suicidal Treatment-Resistant Bipolar Depression; data expected in 4Q 2023 National educational campaign launched to...
-
May 10, 2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it is rescheduling its first quarter quarterly...
-
April 27, 2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, a Delaware Corporation, today announced that it will release its first...
-
March 30, 2023
Over the past 12 months, the Company reinitiated its psychiatry development program post pandemic, transferred manufacturing of NRX-101 to the US, and initiated a clinical trial in suicidal...
Click here to view our corporate presentation or on the image below
![]() |